Adrian P Mander

List of Publications by Citations

84 papers	2,889 citations	25 h-index	53 g-index
85 ext. papers	3,377 ext. citations	4.9 avg, IF	5.18 L-index

#	Paper	IF	Citations
84	Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial. *Lancet, The*, **2011**, 378, 1485-92	40	304
83	Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. *PLoS ONE*, **2015**, 10, e0117383	3.7	295
82	Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. *American Journal of Clinical Nutrition*, **2012**, 96, 748-58	7	222
81	Energy-dense, low-fiber, high-fat dietary pattern is associated with increased fatness in childhood. *American Journal of Clinical Nutrition*, **2008**, 87, 846-54	7	214
80	Is sugar-sweetened beverage consumption associated with increased fatness in children?. *Nutrition*, **2007**, 23, 557-63	4.8	142
79	HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2002**, 72, 184-7	5.5	114
78	Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. *Lancet, The*, **2017**, 389, 2214-2225	40	109
77	Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?. *Trials*, **2014**, 15, 364	2.8	91
76	A prospective analysis of dietary energy density at age 5 and 7 years and fatness at 9 years among UK children. *International Journal of Obesity*, **2008**, 32, 586-93	5.5	87
75	The SkillingsMack Test (Friedman Test when There are Missing Data). *The Stata Journal*, **2009**, 9, 299-305	3.5	85
74	Accelerated longitudinal designs: An overview of modelling, power, costs and handling missing data. *Statistical Methods in Medical Research*, **2017**, 26, 374-398	2.3	83
73	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. *PLoS Medicine*, **2016**, 13, e1002139	11.6	76
72	How much human milk do infants consume? Data from 12 countries using a standardized stable isotope methodology. *Journal of Nutrition*, **2010**, 140, 2227-32	4.1	73
71	A proposed method of bias adjustment for meta-analyses of published observational studies. *International Journal of Epidemiology*, **2011**, 40, 765-77	7.8	63
70	Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. *Contemporary Clinical Trials*, **2010**, 31, 572-8	2.3	55
69	Use of stable-isotope techniques to validate infant feeding practices reported by Bangladeshi women receiving breastfeeding counseling. *American Journal of Clinical Nutrition*, **2007**, 85, 1075-82	7	55
68	Adaptive designs for dual-agent phase I dose-escalation studies. *Nature Reviews Clinical Oncology*, **2013**, 10, 277-88	19.4	49

67	A product of independent beta probabilities dose escalation design for dual-agent phase I trials. *Statistics in Medicine*, **2015**, 34, 1261-76	2.3	49
66	Objectively measured physical activity and fat mass in children: a bias-adjusted meta-analysis of prospective studies. *PLoS ONE*, **2011**, 6, e17205	3.7	49
65	Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. *British Journal of Nutrition*, **2014**, 111, 679-89	3.6	48
64	Moderate ingestion of alcohol is associated with acute ethanol-induced suppression of circulating CTX in a PTH-independent fashion. *Journal of Bone and Mineral Research*, **2009**, 24, 1380-8	6.3	34
63	Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis. *Pharmaceutical Statistics*, **2012**, 11, 91-6	1	30
62	How to design a dose-finding study using the continual reassessment method. *BMC Medical Research Methodology*, **2019**, 19, 18	4.7	29
61	Optimal multistage designs for randomised clinical trials with continuous outcomes. *Statistics in Medicine*, **2012**, 31, 301-12	2.3	29
60	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. *BMJ, The*, **2020**, 369, m115	5.9	25
59	An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. *Statistics in Medicine*, **2006**, 25, 433-45	2.3	24
58	The Skillings-Mack test (Friedman test when there are missing data). *The Stata Journal*, **2009**, 9, 299-305	3.5	24
57	bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials. *Journal of Statistical Software*, **2013**, 54,	7.3	24
56	A phase 2 study of vatalanib in metastatic melanoma patients. *European Journal of Cancer*, **2010**, 46, 2671-3	7.5	23
55	Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans. *Journal of Nutrition*, **2014**, 144, 667-72	4.1	21
54	Minimizing the maximum expected sample size in two-stage Phase II clinical trials with continuous outcomes. *Journal of Biopharmaceutical Statistics*, **2012**, 22, 836-52	1.3	20
53	Variation in the urokinase-plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD. *American Journal of Medical Genetics Part A*, **2004**, 124B, 29-37		19
52	Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points. *European Journal of Cancer*, **2011**, 47, 983-9	7.5	18
51	Do single-arm trials have a role in drug development plans incorporating randomised trials?. *Pharmaceutical Statistics*, **2016**, 15, 143-51	1	18
50	Multiple sclerosis recurrence risk for siblings in an isolated population of Central Sardinia, Italy. *Genetic Epidemiology*, **2002**, 22, 265-71	2.6	17

49	Dietary energy density and adiposity: employing bias adjustments in a meta-analysis of prospective studies. *BMC Public Health*, **2011**, 11, 48	4.1	16
48	Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. *Pharmacoepidemiology and Drug Safety*, **2008**, 17, 601-8	2.6	15
47	Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials. *Statistics in Medicine*, **2017**, 36, 2499-2513	2.3	14
46	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. *Journal of the National Cancer Institute*, **2019**, 111, 1255-1262	9.7	14
45	Weight loss referrals for adults in primary care (WRAP): protocol for a multi-centre randomised controlled trial comparing the clinical and cost-effectiveness of primary care referral to a commercial weight loss provider for 12 weeks, referral for 52 weeks, and a brief self-help intervention [ISRCTN82857232]. *BMC Public Health*, **2014**, 14, 620	4.1	14
44	Escalation strategies for combination therapy Phase I trials. *Pharmaceutical Statistics*, **2012**, 11, 258-66	1	11
43	The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. *JCI Insight*, **2018**, 3,	9.9	11
42	AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials. *PLoS ONE*, **2016**, 11, e0159026	3.7	11
41	Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT. *Health Technology Assessment*, **2018**, 22, 1-104	4.4	11
40	An optimal stratified Simon two-stage design. *Pharmaceutical Statistics*, **2016**, 15, 333-40	1	11
39	Genetic predisposition to an adverse lipid profile limits the improvement in total cholesterol in response to weight loss. *Obesity*, **2013**, 21, 2589-95	8	9
38	The effect of altering eligibility criteria for entry onto a kidney transplant waiting list. *Nephrology Dialysis Transplantation*, **2001**, 16, 816-23	4.3	9
37	An adaptive design for updating the threshold value of a continuous biomarker. *Statistics in Medicine*, **2016**, 35, 4909-4923	2.3	8
36	A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program-AIM-HY INFORM trial. *American Heart Journal*, **2018**, 204, 102-108	4.9	8
35	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. *Trials*, **2020**, 21, 528	2.8	7
34	No difference in the 24-hour interstitial fluid glucose profile with modulations to the glycemic index of the diet. *Nutrition*, **2010**, 26, 290-5	4.8	7
33	Designs for adding a treatment arm to an ongoing clinical trial. *Trials*, **2020**, 21, 251	2.8	6
32	Diet and glycosylated haemoglobin in the 1946 British birth cohort. *European Journal of Clinical Nutrition*, **2009**, 63, 1084-90	5.2	6

31	Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. *Clinical Trials*, **2020**, 17, 147-156	2.2	6
30	Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials. *Biometrical Journal*, **2018**, 60, 903-916	1.5	6
29	An optimised multi-arm multi-stage clinical trial design for unknown variance. *Contemporary Clinical Trials*, **2018**, 67, 116-120	2.3	6
28	How to use published complete case results from weight loss studies in a missing data sensitivity analysis. *Obesity*, **2014**, 22, 996-1001	8	5
27	Bayesian hierarchical methods to interpret the (13)C-octanoic acid breath test for gastric emptying. *Digestion*, **2011**, 83, 96-107	3.6	5
26	Improving outcomes in adults with epilepsy and intellectual disability (EpAID) using a nurse-led intervention: study protocol for a cluster randomised controlled trial. *Trials*, **2016**, 17, 297	2.8	5
25	Admissible multiarm stepped-wedge cluster randomized trial designs. *Statistics in Medicine*, **2019**, 38, 1103-1119	2.3	5
24	Blinded and unblinded sample size reestimation in crossover trials balanced for period. *Biometrical Journal*, **2018**, 60, 917-933	1.5	4
23	The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. *Statistical Methods in Medical Research*, **2015**, 24, 909-19	2.3	4
22	A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2019**, 68, 309-329	1.5	4
21	A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods. *Pharmaceutical Statistics*, **2021**, 20, 462-484	1	4
20	Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately.. *JCO Precision Oncology*, **2021**, 5,	3.6	4
19	Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration. *Statistics in Medicine*, **2017**, 36, 225-241	2.3	3
18	Genetic predisposition to type 2 diabetes is associated with impaired insulin secretion but does not modify insulin resistance or secretion in response to an intervention to lower dietary saturated fat. *Genes and Nutrition*, **2012**, 7, 529-36	4.3	3
17	Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND. *BMJ Open*, **2019**, 9, e028577	3	3
16	Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.. *Statistics in Biopharmaceutical Research*, **2019**, 11, 360-374	1.2	2
15	Weight loss in a commercial setting AuthorsTreply. *Lancet, The*, **2012**, 379, 1003	40	2
14	Application of Bayesian analysis to the doubly labelled water method for total energy expenditure in humans. *Rapid Communications in Mass Spectrometry*, **2018**, 32, 23-32	2.2	2

13	Group sequential crossover trial designs with strong control of the familywise error rate. *Sequential Analysis*, **2018**, 37, 174-203	0.7	2
12	Acute effects of hyperglycaemia on asymmetric dimethylarginine (ADMA), adiponectin and inflammatory markers (IL-6, hs-CRP) in overweight and obese women with metabolic syndrome. *British Journal of Biomedical Science*, **2010**, 67, 216-8	1.6	1
11	A stochastically curtailed single-arm phase II trial design for binary outcomes.. *Journal of Biopharmaceutical Statistics*, **2022**, 1-21	1.3	1
10	Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study. *Trials*, **2019**, 20, 665	2.8	1
9	Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables. *Communications in Statistics - Theory and Methods*, **2021**, 50, 18-34	0.5	1
8	A stochastically curtailed two-arm randomised phase II trial design for binary outcomes. *Pharmaceutical Statistics*, **2021**, 20, 212-228	1	1
7	Optimised point estimators for multi-stage single-arm phase II oncology trials.. *Journal of Biopharmaceutical Statistics*, **2022**, 1-15	1.3	1
6	Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. *BMJ Open*, **2021**, 11, e053669	3	1
5	INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes.. *Trials*, **2022**, 23, 414	2.8	1
4	Bayesian Adaptive Designs for Phase I Trials **2021**, 1-27		
3	Bayesian Adaptive Designs for Phase I Trials **2021**, 1-27		
2	Group sequential clinical trial designs for normally distributed outcome variables.. *The Stata Journal* , **2018**, 18, 416-431	3.5	
1	Accounting for variation in the required sample size in the design of group-sequential trials. *Contemporary Clinical Trials*, **2021**, 107, 106459	2.3	